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ABSTRACT
In the androgen receptor of a patient with androgen insensitivity,
the alanine residue at position 564 in the first zinc cluster of the
DNA-binding domain was substituted by aspartic acid. In other mem-
bers of the steroid receptor family, either valine or alanine is present
at the corresponding position, suggesting the importance of a neutral
amino acid residue at this site. The mutant receptor was transcrip-
tionally inactive, which corresponded to the absence of specific DNA
binding in gel retardation assays, and its inactivity in a promoter
interference assay. Two other receptor mutants with a mutation at
this same position were created to study the role of position 564 in the
human androgen receptor on DNA binding in more detail. Introduc-
tion of asparagine at position 564 resulted in transcription activation
of a mouse mammary tumor virus promoter, although at a lower level
compared with the wild-type receptor. Transcription activation of an
(ARE)2-TATA promoter was low, and binding to different hormone
response elements could not be visualized. The receptor with a leucine
residue at position 564 was as active as the wild-type receptor on a
mouse mammary tumor virus promoter and an (ARE)2-TATA pro-
moter, but interacted differentially with several hormone response
elements in a gel retardation assay. The results of the transcription
activation and DNA binding studies could partially be predicted from
three-dimensional modeling data. The phenotype of the patient was
explained by the negative charge, introduced at position 564. (Endo-
crinology 139: 103–110, 1998)
THE ANDROGEN receptor (AR) gene is composed ofeight exons and encodes a protein of 910 amino acids
with an apparent molecular mass of 110 kDa (1). The AR
belongs to a superfamily of nuclear receptors for steroid
hormones, thyroid hormones, vitamin D, and retinoids.
These receptors are characterized by distinct functional do-
mains: an N-terminal part, involved in transcription activa-
tion, a DNA-binding domain (DBD), a hinge region, and a
C-terminal part involved in ligand binding, dimerization,
and transcription activation (2, 3). The DBD of steroid re-
ceptors is encoded by two exons and consists of two func-
tionally different DNA-binding zinc clusters (4). Steroid re-
ceptors bind to hormone response elements (HREs) as
homodimers, in contrast to several other nuclear receptors
that can heterodimerize with the retinoid X receptor (4).
Although the structure of the DBD is well conserved between
nuclear receptors, several groups of receptors bind to specific
DNA sequences (5). The glucocorticoid receptor (GR) and
estrogen receptor (ER) DBDs interact with distinct, although
related, HREs (4, 6). Three amino acid residues located in the
so-called P box (proximal box) are essential for specific in-
teraction with base pairs from the HRE, located in the major
groove of DNA (7). The GR, the AR, the mineralocorticoid
receptor, and the progesterone receptor recognize the same
HRE (AGAACAnnnTGTTCT) (5). Specificity with respect to
transcription activation is probably introduced by auxillary
factors, which can change the affinity and specificity of bind-
ing sites (4). However, recently Claessens et al. (8) reported
an androgen response element (ARE) in the probasin pro-
moter that is AR specific. The consensus HRE for steroid
receptors is an imperfect palindromic sequence, consisting of
two half-sites, spaced by three nucleotides (9). Binding of the
first receptor molecule enhances binding of the second mol-
ecule. Important determinants for this so-called cooperativ-
ity of binding are the spacing between the two half-sites of
the HRE and protein-protein contacts (9).
Male sex differentiation and development proceed under
direct control of the male sex hormones testosterone and
5a-dihydrotestosterone, and the actions of both androgens
are mediated by the AR. Mutations in the AR gene of 46,XY
individuals are associated with the androgen insensitivity
syndrome (AIS), a disorder of sex differentiation. Many ab-
normalities have been described, causing a wide spectrum of
phenotypes, ranging from subjects with an external female
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phenotype and absence of Mullerian and Wolffian duct de-
rivatives, which is the complete form of AIS, to a phenotype
with ambiguous genitalia, called partial AIS (10). The most
frequently reported defects are point mutations in the ligand-
and DNA-binding domains of the AR (10, 11).
In the present study a mutation in exon 2 of a subject with
complete AIS is reported. The alanine residue at position 564
in the DBD was substituted into aspartic acid (mutant
A564D). The effect of the A564D mutation on AR function
was investigated, as was the effect of an asparagine substi-
tution (mutant A564N) and a leucine substitution (mutant




Primers were obtained from Pharmacia Biotech Benelux (Roosendaal,
The Netherlands). [g-32P]ATP (SA, 3000 Ci/mmol) was obtained from
Amersham (Little Chalfont, UK). 17b-Hydroxy-17a-[3H]methyl-4,9,11-
estratrien-3-one ([3H]R1881; SA, 85 Ci/mmol), and unlabeled R1881
were purchased from New England Nuclear-DuPont de Nemours
(s’Hertogenbosch, The Netherlands). The double stranded probe, con-
taining an ARE, derived from the tyrosine aminotransferase (TAT) pro-
moter 59-TCGACTGTACAGGATGTTCTAGCTACT-39 (half-sites are
underlined) was obtained from Promega (Woerden, The Netherlands).
The 27-bp oligonucleotides, used to produce two other double stranded
probes, 59-TCGACGTTACAAACTGTTCTAGCTACT-39 and 59-TC-
GACGGTACAGTTTGTTCTAGCTACT-39 (half-sites are underlined),
containing, respectively, the strongest ARE from the mouse mammary
tumor virus (MMTV) promoter (12) and a consensus ARE (13), were
obtained from Pharmacia Biotech Benelux.
Clinical data
The patient exhibiting female external genitalia, atrophic epididymi-
des, and vasa deferentia was diagnosed as having AIS at the age of 1 yr
in the absence of a positive family history. A blind ending vagina was
present, the uterus was absent, and testes with a normal histology for
a boy of this age were present in the inguinal canal. Testosterone syn-
thesis disorders were excluded as a cause of the 46,XY sex reversal.
Genital skin fibroblasts (GSF) were obtained from the index patient for
Scatchard analysis and structural analysis of the AR gene. AR sequence
analysis of relatives was performed on white blood cell genomic DNA.
Mutation detection
PCR-single strand conformation polymorphism analysis and direct
sequencing were performed as described previously (14).
Ligand binding study
For determination of ligand binding characteristics of the AR of the
AIS subject, GSF were incubated with serial dilutions [3H]R1881 (0.02,
0.05, 0.3, 1.0, and 3.0 nm, respectively) in serum-free medium. The
binding assay was performed as described previously (14).
Western blot analysis
AR protein, derived from GSF or transiently transfected Chinese
hamster ovary (CHO) cells was immunoprecipitated and analyzed by
Western immunoblotting according to the method of Ris-Stalpers et al.
(15).
Construction of AR expression vectors
pAR(0), a human wild-type AR complementary DNA expression
plasmid, was described previously (1). Expression plasmids encoding
the various mutants, pAR(A564D), pAR(A564N), and pAR(A564L), re-
spectively, were constructed by site-directed mutagenesis. The KpnI-
AspI-digested fragment of pAR(0) was exchanged with mutated KpnI-
AspI fragments, generated in two separate PCR amplifications (16).
Sense primer 470A (14), located upstream of the KpnI site in exon 1, was
combined with an antisense primer, containing the mutation (antisense
primers: construct A564D, 59-CATGTGAGAtCTCCATAGTGACAC-39;
construct A564N, 59-CATGTGAGAttTCCATAGTGACACCC-39; con-
struct A564L, 59-CATGTGAGAagTCCATAGTGACACCC39), and a
sense primer, introducing the mutation (sense primers: construct
A564D, 59-GTGTCACTATGGAGaTCTCACATG-39; construct A564N,
59-GGTGTCACTATGGAaaTCTCACATGTGG-39; construct A564L, 59-
GGTGTCACTATGGActTCTCACATGTGG-39), was used in combina-
tion with an antisense primer, 14NB (14), located downstream of a
unique AspI site in exon 4. One microliter of both PCR products was used
as template in a second PCR reaction using primers 470A and 14NB. The
resulting PCR fragment was digested with KpnI and AspI, and ex-
changed for the corresponding wild-type fragment in pAR0.
pSG5AR(0), a human wild-type AR complementary DNA expression
vector (provided by Dr. A. C. B. Cato, Karlsruhe, Germany) was
used for transient transfection of COS-1 cells. pSG5AR(A564D),
pSG5AR(A564N), and pSG5AR(A564L) were constructed by exchanging
the 472-bp KpnI-AspI insert from pSG5AR(0) and the KpnI-AspI fragment
from the pSVAR plasmids, encoding the variant ARs.
MMTV-LUC reporter plasmid, cytomegalovirus (CMV)-LUC, the
CMV-(ARE)3-LUC reporter plasmids, and pJH4-(ARE)2-TATA-LUC,
containing the TATA box and an Sp1 site derived from the Oct-6 gene
promoter have been described previously (17–19).
Cell culture conditions and transfections
GSF and COS-1 cells were cultured as previously described (20). CHO
cells were cultured according to the COS-1 cell culture protocol. The
CHO cells used for transcription activation studies and promoter in-
terference assays were plated in 7- or 11-cm2 (promoter interference
assay) wells and grown for 24 h. Cells were cotransfected, using the
calcium-phosphate method, with AR expression plasmid (10 ng/ml
precipitate) and reporter plasmid (2 mg/ml precipitate) (21). Carrier
DNA (pTZ19) was added to a total of 20 mg DNA/ml precipitate, and
90 ml precipitate were added per well. In the promoter interference
assay, 300 ng AR expression plasmid and 30 ng reporter plasmid [CMV-
LUC or CMV-(ARE)3-LUC], respectively, were added per ml precipitate.
pTZ19 was added to a total of 20 mg DNA/ml precipitate, and 250 ml
precipitate were added to 11-cm2 wells. The transfection and luciferase
assay were performed as described previously (22). Both transcription
activation studies and the promoter interference assay were performed
at least three times in triplicate, using three independent isolates of
expression plasmid. In the case of transcription activation studies, lu-
ciferase activity was expressed relative to basal activity measured after
culture in the absence of hormone. For promoter interference studies,
luciferase activity in cells, transfected with CMV-(ARE)3-LUC and AR
expression plasmid and cultured in the absence of hormone was set at
100%. Inhibition of promoter activity in the presence of hormone was
expressed relative to this 100% activity. CHO cells used for expression
studies by Western blotting were also transiently transfected by the
calcium-phosphate method. To this end, cells were plated in 175-cm2
culture flasks and transiently transfected with 20 mg expression plasmid.
COS-1 cells were plated in 80-cm2 culture flasks and transiently trans-
fected with 9.4 mg expression plasmid, using the diethylaminoethyl-
dextran method (23). Twenty-four hours before harvesting, CHO and
COS-1 cells were washed and incubated with medium containing 1 nm
R1881.
Gel retardation assays
Transfected COS-1 cells were collected in 5 ml PBS, and the pellet was
resuspended in extraction buffer [10 mm NaH2PO4 (pH 7.4), 0.4 m KCl,
1 mm EDTA, 10% (vol/vol) glycerol, 0.5 mm bacitracin, 0.5 mm leu-
peptin, 0.6 mm phenylmethylsulfonylfluoride, and 10 mm dithiothreitol]
and subjected to four freeze-thaw cycles, followed by 10-min centrifu-
gation at 400,000 3 g at 4 C in a TLA120.2 rotor (Beckman, Fullerton, CA)
in a Beckman Optima TLX ultracentrifuge. The TAT ARE-containing
probe (59-TCGACTGTACAGGATGTTCTAGCTACT-39) (halfsites are
underlined) was obtained from Promega. Two other probes were pro-
duced by annealing a 27-bp oligonucleotide with an oligonucleotide of
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complementary sequence. One of them (59-TCGACGTTACAAACTGT-
TCTAGCTACT-39) (half-sites are underlined) contains the strongest ARE
from the MMTV promoter (12), and the other probe (59-TCGACGGTA-
CAGTTTGTTCTAGCTACT-39) (half-sites are underlined) contains a con-
sensus ARE (13). The ARE-containing probes were end labeled using T4
polynucleotide kinase, and double stranded probe was purified from a
4% acrylamide gel in 0.5 3 TBE (1 3 TBE 5 50 mm Tris base, 50 mm boric
acid, and 1 mm EDTA, pH 8.6). Cellular extracts were incubated in
binding buffer [10 mm HEPES (pH 7.9), 60 mm KCl, 1 mm dithiothreitol,
1 mm EDTA, and 4% Ficoll] and 1 mg polydeoxyinosinic-deoxycitidylic
acid in the absence or presence of the polyclonal AR antibody Sp197
(10-fold diluted) (24). After an incubation period of 10 min on ice, 2 ml
purified DNA probe (50,000 cpm/ml) were added, and incubation was
continued for 20 min at room temperature. The 20-ml sample was sep-
arated on a 4% polyacrylamide gel in 0.5 3 TBE. Gels were fixed for 10
min in 10% acetic acid-10% methanol, and subsequently dried and
exposed.
Molecular modeling
The crystal structure of the rat GR DBD bound to a glucocorticoid
response element was used as a basis upon which the three-dimensional
(3-D) AR models were built. The 3-D model of AR bound to a glucocor-
ticoid response element has previously been described (25). The A564D,
A564N, and A564L mutants were built according to the same strategy
as that used to build the wild-type model. Briefly, the side-chains of the
AR mutants that were substituted in the GR model were placed in
energetically favorable conformations using the SMD program (26). The
whole system was then energy minimized with the AMBER program
(Pearlman et al., 1991, University of California, San Francisco, CA).
During the optimization process, the oligonucleotide was kept frozen to
prevent unrealistic deviation from the initial crystal structure. Moreover,
positional restraints on the backbone and on side-chains of conserved
residues were applied and gradually released during the optimization.
Figure 5A was generated with the Insight II viewer (Biosym Technol-




Genomic DNA of the index patient was used to amplify the
coding part and intronic sequences flanking the exons of the
AR gene, followed by single strand conformation polymor-
phism analysis performed under two different conditions.
An aberrant banding pattern was found for exon 2, which
encodes the first zinc cluster of the DBD. Direct sequencing
showed a single nucleotide substitution at codon 564 (C to A)
that resulted in substitution of alanine to aspartic acid (Fig.
1). The numbering of amino acid residues throughout the text
is based on a total number of 910 amino acid residues in the
human AR (1). The mutation created a BglII site, which was
used to investigate the segregation of this mutation in the
family of the index patient. The mother and grandmother of
the index patient were heterozygous carriers of this AR mu-
tation (results not shown).
Functional properties of the mutant receptor
The AR protein was isolated from GSF obtained from the
index subject. Molecular mass was checked by immunoblot-
ting after immunoprecipitation. The AR protein migrated as
a normal 110/112-kDa doublet on SDS-PAGE (data not
shown). For Scatchard analysis, cultured GSF were incubated
for 1 h with increasing concentrations of [3H]R1881 in either
the presence or absence of a 200-fold molar excess of non-
radioactive R1881. Both the Kd (0.07 nm) and the maximal
binding capacity (58 fmol/mg protein) values were within
the normal range (Kd, 0.03–0.13 nm; binding capacity, 39–169
fmol/mg protein), indicating that ligand binding was not
affected by the mutation.
Transcriptional activity of AR A564D
AR A564D was inactive in CHO cells cotransfected with
(ARE)2-TATA-LUC, in contrast to the wild-type AR (Fig. 2A).
The promoter of this reporter construct contains a TATA box
and an Sp1 site derived from the Oct-6 gene promoter, and
two AREs (19). In general, comparable levels of wild-type
and mutant receptor protein were expressed in transiently
transfected CHO cells, as verified by SDS-PAGE and immu-
noblotting (for example, see Fig. 3C). AR A564D was also
unable to activate transcription from the complex MMTV
promoter in CHO cells (Fig. 2B).
In vivo DNA binding of AR A564D
In vivo DNA binding was studied using a promoter in-
terference assay. CHO cells were cotransfected with CMV-
(ARE)3-LUC. Three consensus AREs were inserted between
the TATA box of the constitutively active CMV promoter and
the transcription start site of the luciferase gene (13). Binding
of the AR hinders the assembly of a transcription initiation
complex and, therefore, also interferes with the expression of
the luciferase gene (18). The level of inhibition is taken as a
measure of specific DNA binding. In the presence of 1 nm
R1881, the wild-type AR showed a 48% reduction of lucif-
erase activity, whereas no reduction was seen in cells co-
transfected with AR A564D (Fig. 2C). The AR could sequester
factors that are essential for the transcriptional activity of the
CMV promoter (squelching). However, no reduction of lu-
ciferase expression was seen in cells cotransfected with
CMV-LUC (Fig. 2C).
Transcriptional activities of AR A564N and AR A564L
To investigate whether the inactivity of AR A564D was
caused by steric hindrance or by a conformational change
FIG. 1. Sequence of the AR DBD with the A3D mutation, located in
the first zinc cluster. The mutation found in the index patient’s AR is
present at position 564 of the AR DBD, located near the P box, of which
the circled amino acid residues are involved in ARE recognition. The
boxes indicate amino acid residues that interact with the phosphate
backbone of DNA either at specific (black boxes) or at nonspecific sites
(open boxes) (25, 28). The second zinc cluster contains the D box, which
is involved in dimerization with the other AR receptor. The first part
of the nuclear localization signal (NLS) is also shown (underlined).
The numbering of the various codons is based on a total of 910 amino
acid residues in the human AR (1).
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due to the introduction of a negative charged amino acid
residue, the alanine residue was replaced by either a leucine
residue (A564L) or an asparagine residue (A564N). Leucine
has, like the aspartic acid residue, a larger side-chain, but is
a neutral amino acid, as is the alanine residue present in the
wild-type receptor. Asparagine has also a larger side-chain,
but is a polar amino acid residue. CHO cells were transiently
cotransfected with AR expression plasmids and (ARE)2-
TATA-LUC. Wild-type AR and AR A564L showed compa-
rable activation of the minimal promoter at increasing
amounts of R1881, whereas AR A564N showed strongly
reduced transcription activation compared with the wild-
type AR (Fig. 3A). On the more complex MMTV promoter,
AR A564L showed activity comparable to that of the wild-
type receptor, and AR A564N displayed a low level of hor-
mone-induced transcription activation (Fig. 3B). All proteins
were expressed, and in general, expression levels were com-
parable (Fig. 3C).
In vivo DNA binding of AR A564N and AR A564L
DNA binding was studied in CHO cells cotransfected with
CMV-(ARE)3-LUC (Fig. 3D). In contrast to the wild-type AR,
luciferase expression was not lowered after cotransfection of
cells with AR A564N and culture in the presence of hormone.
AR A564L showed 38% inhibition, which was significantly
different (P , 0.05) from the 48% inhibition observed for the
wild-type receptor. Protein expression levels were identical
for all mutant receptors (see also Fig. 3C).
In vitro DNA binding comparing different AREs
The DNA-binding capacities of the wild-type and the dif-
ferent AR mutants were tested in vitro in gel retardation
assays, using probes containing various AREs. AR was pro-
duced in transfected COS-1 cells. The amount of receptor
protein was checked by Western blotting, followed by im-
munostaining. Comparable amounts of AR in COS-1 cellular
extracts were incubated with a 32P-labeled probe in either the
absence or presence of polyclonal antibody Sp197, which
stabilizes AR dimers bound to the DNA (24). Wild-type AR
and AR A564L did bind to the ARE derived from the TAT
promoter (Fig. A, lanes 3 and 9), whereas binding of AR
A564D and AR A564N could not be detected (Fig. 4A, lanes
5 and 7). Gel shift assays were also performed with two other
probes. One of the probes contained the strongest ARE from
the MMTV promoter (12), which was also present in (ARE)2-
TATA-LUC. The other probe contained a consensus ARE
(13), which was also cloned behind the constitutively active
CMV promoter, that was used for promoter interference
studies. Wild-type AR was able to shift the probes in the
presence of antibody, indicative of specific DNA binding
(Fig. 4B, lane 3, and Fig. 4C, lane 3). Neither probe could be
shifted with AR A564D (Fig. 4B, lane 5, and Fig. 4C, lane 5)
or AR A564N (Fig. 4B, lane 7, and Fig. 4C, lane 7), although
A564N showed transcription activation on a complex MMTV
promoter and even on a minimal ARE promoter. AR A564L
interacted with both probes, although less efficiently than the
wild-type AR, which is in agreement with the results of the
promoter interference assay (Fig. 4B, lane 9, and 4C, lane 9).
Molecular modeling
The alanine residue at position 564 is buried, as it is in-
volved in a hydrophobic cluster that is mainly formed by
leucine 551, isoleucine 552, cysteine 610, alanine 613, and
methionine 615 (Figs. 1 and 5, A and B). The Ca-Cb bond of
FIG. 2. A, Transcriptional activity of AR A564D at the (ARE)2-TATA promoter. CHO cells were cotransfected with (ARE)2-TATA-LUC reporter
plasmid and the wild-type or mutant expression plasmid. Twenty-four hours after transfection, cells were cultured with medium containing increasing
concentrations of R1881 for another 24 h. Each data point was tested in triplicate. Induction of luciferase activity was calculated from five different
experiments (n 5 5); symbols represent the mean 6 SEM (F, wild type; E, A564D). Transcription activation by AR A564D was significantly different
from that by the wild-type AR (by Student’s t test, P 5 0.05). B, Transcriptional activity of AR A564D at the MMTV promoter. Transcription activation
properties were determined by cotransfection of CHO cells with MMTV-LUC reporter plasmid and either the wild-type or mutant ARA564D expression
plasmid. After 24 h, the cells were incubated with different concentrations of R1881 and incubated for another 24 h before a luciferase assay was
performed. Each data point was tested in triplicate. Induction of luciferase activity was calculated from three different experiments; symbols represent
the mean 6 SEM (F, wild type; E, A564D). Transcription activation by AR A564D was significantly different from that by wild-type AR (by Student’s
t test, P 5 0.05). C, Promoter interference of wild-type AR and AR A564D. CHO cells were transiently transfected with expression plasmid and
CMV-(ARE)2-LUC reporter plasmid. Twenty-four hours after transfection, cells were cultured in the absence or presence of 1 nM R1881 and incubated
for another 24 h before performing a luciferase assay. Each data point was tested in triplicate. CMV-LUC reporter construct cotransfected with pAR0
was taken as a control (n 5 2). The luciferase signal measured in the absence of R1881 was arbitrarily set at 100%, and activities measured in the
presence of 1 nM R1881 were related to these values. The mean promoter activity 6 SEM in the presence of hormone is represented.
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the alanine residue at position 564 is directed toward the
cysteine residue at position 610 in the protein core. The
backbone of residue 564 is hydrogen bonded with the back-
bone of histidine residue 561, as both residues belong to a
b-hairpin (Fig. 5B). They are located at the same side of the
hairpin at facing positions. The histidine residue at position
561 is involved in direct contacts with DNA and participates
in ARE recognition (Fig. 5B). Molecular modeling showed
that in the A564D mutant, the aspartic acid residue is still
buried. However, burying of charged residues is unfavorable
unless a compensatory charge forms a salt bridge and is also
buried at the same site. The only way AR A564D can take a
more favorable conformation is by breaking of the b-hairpin
and the hydrogen bonding with the histidine residue at po-
sition 561. This most likely affects the conformation of the
histidine residue 561, resulting in disturbed ARE recognition.
The asparagine residue in A564N should lead to smaller
perturbations because it will remain buried, although aspar-
agine is a polar residue. The modeling showed that hydrogen
bonding of asparagine with threonine 566 may roughly com-
FIG. 3. A, Transcription activation by the wild-type receptor and A564N and A564L using an (ARE)2-TATA-LUC reporter gene. CHO cells were
cotransfected with (ARE)2-TATA-LUC reporter plasmid and either the wild-type or one of the mutant expression plasmids. Twenty-four hours
after transfection, cells were cultured in medium containing increasing concentrations of R1881 for another 24 h. Each data point was tested
in triplicate. Induction of luciferase activity was calculated from five different experiments (n 5 5); symbols represent the mean 6 SEM (F, wild
type; E, A564N; , A564L). Transcription activation by AR A564N was significantly different from that displayed by the wild-type AR (by
Student’s t test, P 5 0.05). B, Transcription activation by the wild-type receptor, AR A564N, and AR A564L, using an MMTV-regulated reporter
gene. CHO cells were cotransfected with MMTV-LUC reporter plasmid and either the wild-type or one of the mutant expression vectors. After
24 h, cells were cultured with increasing concentrations of R1881 for 24 h before a luciferase assay was performed. Each data point was tested
in triplicate. Induction of luciferase activity, presented relative to basal activity in the absence of R1881, was calculated from five different
experiments; symbols represent the mean 6 SEM (F, wild type; E, A564N; , A564L). Transcription activation by AR A564N was significantly
different from that displayed by the wild-type receptor (by Student’s t test, P 5 0.05). C, Western blot analysis of wild-type and mutated ARs
after transient transfection in CHO cells. Culture flasks with CHO cells were transfected with expression plasmid, and after 48 h, cell lysates
were prepared. From these lysates, the receptor was immunoprecipitated with monoclonal antibody F39.4.1 and separated on a SDS-PAGE
gel. After blotting, receptor protein was detected with polyclonal antibody Sp061 and an alkaline phosphatase-coupled goat antirabbit antibody.
Lane 1, Wild-type AR; lane 2, AR A564D; lane 3, AR A564N; lane 4, AR A564L. D, Promoter interference assay of AR A564N and AR A564L.
The DNA binding properties of the mutated receptors were also tested in intact cells. CHO cells were transiently transfected with expression
plasmid and CMV-(ARE)2-LUC reporter plasmid. Twenty-four hours after transfection, cells were cultured in the absence or presence of 1 nM
R1881 and incubated for another 24 h before performing a luciferase assay. Each data point was tested in triplicate. The CMV-LUC reporter
construct cotransfected with pAR0 was taken as a control (n 5 2). The luciferase signal measured in the absence of R1881 was arbitrarily set
at 100%, and activities measured in the presence of 1 nM R1881 were calculated relative to these values. The mean promoter activity 6 SEM
in the presence of hormone is represented (n 5 4). *, Significantly different from inhibition shown by the wild-type receptor (by Student’s t test,
P , 0.05).
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FIG. 5. A, View of the hydrogen bonding between the alanine residue
at position 564 and the histidine residue at position 561. The hydrogen
bonding is shown by the dashed lines. Also shown are residues con-
stituting the hydrophobic pocket in which the alanine residue at
position 564 is buried (i.e. leucine 551, isoleucine 552, threonine 566,
alanine 613, and methionine 615). The backbone is shown by thin
lines, and the side-chains are shown as thick lines. B, Schematic view
of part of the ARE and the wild-type AR. Helix I, helix III, and the
side-chains of the histidine residue at position 561 and the alanine
residue at position 564 (ball and stick) are shown. The histidine
residue and the alanine residue belong to a small b-hairpin (strands
shown as thick arrows), and the histidine residue makes direct con-
tacts with DNA. Part of the ARE is displayed as long thin antiparallel
arrows.
Materials and Methods. The position of the shifted complex is indi-
cated by an arrow; FP indicates the position of the free 32P-labeled
probe. A, The probe contained an ARE, derived from the TAT pro-
moter. Lane 1, No receptor protein; lanes 2 and 3, wild-type AR; lanes
4 and 5, AR A564D; lanes 6 and 7, AR A564N; lanes 8 and 9, AR
A564L; lane 10, free probe. After incubation of the probe with the
antibody, no specific shifted band could be seen. B, The probe con-
tained the strongest ARE from the MMTV promoter (12). Lane 1, No
receptor protein; lanes 2 and 3, wild-type AR; lanes 4 and 5, AR
A564D; lanes 6 and 7, AR A564N; lanes 8 and 9, AR A564L. C, The
probe contained a consensus ARE (13). Lane 1, No receptor protein;
lanes 2 and 3, wild-type AR; lanes 4 and 5, AR A564D; lanes 6 and 7,
AR A564N; lanes 8 and 9, AR A564L.
FIG. 4. Gel retardation assay with three different ARE probes. A
labeled ARE probe (50,000 cpm) was incubated with nuclear extracts
prepared from transiently transfected COS-1 cells. Incubations were
performed in the absence (2) or presence (1) of the polyclonal anti-
body Sp197. The complexes were analyzed by PAGE as described in
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pensate for the unfavorable burying of polar atoms. Mod-
eling of the A564L mutant showed that the larger leucine
side-chain can be accommodated without difficulties in the
hydrophobic pocket. Burying of the larger hydrophobic sur-
face may even provide additional stability to the AR. There-
fore, the leucine mutant was not expected to significantly
perturb DNA recognition.
Discussion
The DBD is the most conserved region within the nuclear
receptor family. Characteristic are the eight cysteines in this
domain, forming the two zinc clusters. Zinc ion-coordinated
binding is essential for proper folding and DNA binding. The
structure of the DBDs of the GR and ER, respectively, in
complex with their response element on the DNA was solved
by x-ray crystallography. Almost similar conformations were
displayed (28, 29). The AR DBD is more closely related to the
GR DBD sequence than to the ER DBD sequence. Fifteen
amino acid residues in the AR DBD, which is defined as a
65-amino acid domain starting at lysine 548, are different
from the GR DBD (30, 31). Only 5 of them are located in the
first zinc cluster, and 1 of these should be considered a
conservative change according to the chemical properties of
its side-chain (31). Therefore, it seems reasonable to deduce
the structural consequences of mutations in the AR DBD
from the 3-D structure of the GR DBD. In the present paper,
the characterization of a mutation at position 564 in the first
zinc cluster of the DBD of the human AR is reported. Mu-
tations in the first zinc cluster of the AR have been described
previously (11). Some of them disrupt the zinc cluster struc-
ture because 1 of the cysteines is substituted, resulting in a
complete AIS phenotype (11). Alanine 564 is partially con-
served in other members of the receptor family. At the cor-
responding position in the vitamin D receptor, an alanine
residue is present as well (32). In the human ER, human GR,
human progesterone receptor, and human mineralocorticoid
receptor, a valine residue is located at the corresponding
position, implying that the presence of a neutral amino acid
residue at this position is critical for proper interaction of the
receptor with DNA (6, 30, 33, 34). In the AR of the patient,
described in this report, alanine was substituted by the neg-
atively charged aspartic acid residue. The aspartic acid res-
idue is located upstream of an a-helical region that is exposed
to the major groove of DNA and downstream of cysteine 560,
histidine 561, and tyrosine 562, which are involved in specific
as well as nonspecific contacts with the phosphate backbone
of the DNA (28). Substitution of the latter residues by non-
conservative amino acids in the GR resulted in loss of func-
tion (in vivo), and in vitro reduced DNA binding affinity was
seen (35). Warriar et al. (36) substituted the cysteine residue
at position 560 in the human AR by a serine residue. Al-
though this is a relatively conservative change, decreased
DNA binding and transcription activation were observed,
which were attributed to the instability of the AR mutant-
DNA complex.
We showed that AR A564D displayed defective transcrip-
tion activation. Specific binding to DNA, which was studied
in vitro by gel retardation assays with oligonucleotide probes
containing different AREs and in vivo with a promoter in-
terference assay, could not be detected. From 3-D modeling
studies, it became clear that the alanine residue at position
564 is buried in a hydrophobic cluster (Figs. 1 and 5A). A
hydrogen bond is formed between the backbone of alanine
564 and the backbone of histidine 561. This latter residue is
involved in direct interaction with the phosphate backbone
of the DNA and is conserved in other nuclear receptors. Yagi
et al. (37) reported a patient with hereditary 1,25-dihy-
droxyvitamin D-resistant rickets caused by substitution of
the conserved histidine at position 35 of the vitamin D re-
ceptor, comparable to histidine 561 in the AR. The phenotype
of the patient was caused by perturbation of the conserved
site that contacts the phosphate backbone of DNA. For AR
A564D, the computer model displayed almost the exact con-
formation as that seen for the wild type, showing that there
is no steric hindrance due to the mutation. However, buried
charged residues are only observed in proteins when they
can form salt bridges with residues of opposite charge.
Therefore, the modeled conformation appears unlikely.
Probably, aspartic acid 564 adopts a more favorable confor-
mation, and as a result, the main chain hydrogen bond be-
tween aspartic acid 564 and histidine 561 will be broken,
which has consequences with respect to DNA binding.
To investigate the role of the alanine residue at position 564
in more detail, the residue was also replaced by an aspara-
gine or a leucine residue. 3-D modeling predicted that in-
troduction of an asparagine residue should have intermedi-
ate effects with respect to transcription activation. Hydrogen
bonding between asparagine 564 and threonine 566 might
compensate for unfavorable burying of the polar amino acid
residue. Substitution by an asparagine residue resulted in a
less stable AR-DNA complex, which had clear consequences
for transcription activation on a minimal (ARE)2-TATA pro-
moter and to a lesser extent on a complex MMTV promoter.
DNA binding was not observed in vitro by gel retardation
analysis. DNA-binding capacity remained undetectable,
even when studied in whole cells. However, the functionality
of AREs is determined by additional transcription factor-
binding sites in the vicinity of AREs. Interaction with other
proteins might stabilize the AR-DNA complex. This might
explain as well the stronger activation of AR A564N on the
MMTV promoter compared with its activity on the minimal
(ARE)2-TATA promoter (8, 38, 39).
Modeling showed that no particular constraint resulted
from the larger size of the leucine residue. It was predicted
that the leucine residue, because of its larger hydrophobic
surface, provides even more favorable stability to the AR.
However, reduced DNA binding affinity, in vitro as well as
in vivo, was observed for AR A564L. Transcription activation
was comparable with activation displayed by the wild-type
AR. Apparently, molecular modeling has some limitations
with respect to the prediction of complex interactions, which
might be explained by the fact that the model was based
upon the crystal structure, which was solved for the GR DBD.
In addition, functional studies were performed with the in-
tact receptor and not only the DBD.
In conclusion, the negative charge introduced by the as-
partic acid residue destabilizes the normal conformation of
the AR DBD, resulting in disturbed ARE recognition, in
agreement with the phenotype of the patient expressing this
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mutant receptor. Results from the functional assays were
partially supported by predictions made by 3-D modeling.
Although not predicted by molecular modeling, steric hin-
drance might have an impact on the DNA-binding capacities
of AR A564N and AR A564L.
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